Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Arch Rheumatol ; 38(2): 189-199, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37680507

ABSTRACT

Objectives: This study aims to evaluate the effects of exercise training on intramuscular lipid content and genes related to insulin pathway in patients with systemic autoimmune myopathies (SAMs). Patients and methods: Between January 2016 and May 2019, a total of seven patients with dermatomyositis (DM; 3 males, 4 females; mean age: 49.8±2.3 years; range, 43 to 54 years), six with immune mediated necrotizing myopathy (IMNM; 3 males, 3 females; mean age: 58.5±10.6 years; range, 46 to 74 years), and 10 control individuals (CTRL group; 4 males, 6 females; mean age: 48.7±3.9 years; range, 41 to 56 years) were included. The muscle biopsy before and after the intervention was performed to evaluate the intramuscular lipid content. Patients underwent a combined exercise training program for 12 weeks. Skeletal muscle gene expression was analyzed and the DM versus CTRL group, DM pre- and post-, and IMNM pre- and post-intervention were compared. Results: The DM group had a higher intramuscular lipid content in type II muscle fibers compared to the CTRL group. After the intervention, there was a reduction of lipid content in type I and II fibers in DM and IMNM group. The CTRL group showed a significantly higher expression of genes related to insulin and lipid oxidation pathways (AMPKß2, AS160, INSR, PGC1-α, PI3K, and RAB14) compared to the DM group. After exercise training, there was an increase gene expression related to insulin pathway and lipid oxidation in DM group (AMPKß2, AS160, INSR, PGC1-α, PI3K, and RAB14) and in IMNM group (AKT2, AMPKß2, RAB10, RAB14, and PGC1-α). Conclusion: Exercise training attenuated the amount of fat in type I and II muscle fibers in patients with DM and IMNM and increased gene expression related to insulin pathways and lipid oxidation in DM and IMNM. These results suggest that exercise training can improve the quality and metabolic functions of skeletal muscle in these diseases.

2.
Front Immunol ; 14: 1174020, 2023.
Article in English | MEDLINE | ID: mdl-37287969

ABSTRACT

Objective: To analyze the potential impact of sociodemographic, clinical and biological factors on the long-term cognitive outcome of patients who survived moderate and severe forms of COVID-19. Methods: We assessed 710 adult participants (Mean age = 55 ± 14; 48.3% were female) 6 to 11 months after hospital discharge with a complete cognitive battery, as well as a psychiatric, clinical and laboratory evaluation. A large set of inferential statistical methods was used to predict potential variables associated with any long-term cognitive impairment, with a focus on a panel of 28 cytokines and other blood inflammatory and disease severity markers. Results: Concerning the subjective assessment of cognitive performance, 36.1% reported a slightly poorer overall cognitive performance, and 14.6% reported being severely impacted, compared to their pre-COVID-19 status. Multivariate analysis found sex, age, ethnicity, education, comorbidity, frailty and physical activity associated with general cognition. A bivariate analysis found that G-CSF, IFN-alfa2, IL13, IL15, IL1.RA, EL1.alfa, IL45, IL5, IL6, IL7, TNF-Beta, VEGF, Follow-up C-Reactive Protein, and Follow-up D-Dimer were significantly (p<.05) associated with general cognition. However, a LASSO regression that included all follow-up variables, inflammatory markers and cytokines did not support these findings. Conclusion: Though we identified several sociodemographic characteristics that might protect against cognitive impairment following SARS-CoV-2 infection, our data do not support a prominent role for clinical status (both during acute and long-stage of COVID-19) or inflammatory background (also during acute and long-stage of COVID-19) to explain the cognitive deficits that can follow COVID-19 infection.


Subject(s)
COVID-19 , Cognitive Dysfunction , Adult , Humans , Female , Middle Aged , Aged , Male , SARS-CoV-2 , Post-Acute COVID-19 Syndrome , Cognitive Dysfunction/epidemiology , Cytokines
3.
Neuro Oncol ; 25(1): 185-198, 2023 01 05.
Article in English | MEDLINE | ID: mdl-35640920

ABSTRACT

BACKGROUND: Supratentorial RELA fusion (ST-RELA) ependymomas (EPNs) are resistant tumors without an approved chemotherapeutic treatment. Unfortunately, the molecular mechanisms that lead to chemoresistance traits of ST-RELA remain elusive. The aim of this study was to assess RELA fusion-dependent signaling modules, specifically the role of the Hedgehog (Hh) pathway as a novel targetable vulnerability in ST-RELA. METHODS: Gene expression was analyzed in EPN from patient cohorts, by microarray, RNA-seq, qRT-PCR, and scRNA-seq. Inhibitors against Smoothened (SMO) (Sonidegib) and Aurora kinase A (AURKA) (Alisertib) were evaluated. Protein expression, primary cilia formation, and drug effects were assessed by immunoblot, immunofluorescence, and immunohistochemistry. RESULTS: Hh components were selectively overexpressed in EPNs induced by the RELA fusion. Single-cell analysis showed that the Hh signature was primarily confined to undifferentiated, stem-like cell subpopulations. Sonidegib exhibited potent growth-inhibitory effects on ST-RELA cells, suggesting a key role in active Hh signaling; importantly, the effect of Sonidegib was reversed by primary cilia loss. We, thus, tested the effect of AURKA inhibition by Alisertib, to induce cilia stabilization/reassembly. Strikingly, Alisertib rescued ciliogenesis and synergized with Sonidegib in killing ST-RELA cells. Using a xenograft model, we show that cilia loss is a mechanism for acquiring resistance to the inhibitory effect of Sonidegib. However, Alisertib fails to rescue cilia and highlights the need for other strategies to promote cilia reassembly, for treating ST-RELA tumors. CONCLUSION: Our study reveals a crucial role for the Hh pathway in ST-RELA tumor growth, and suggests that rescue of primary cilia represents a vulnerability of the ST-RELA EPNs.


Subject(s)
Ependymoma , Supratentorial Neoplasms , Humans , Hedgehog Proteins , Cilia/metabolism , Cilia/pathology , Aurora Kinase A/genetics , Ependymoma/pathology , Supratentorial Neoplasms/pathology , Transcription Factor RelA
4.
World Neurosurg ; 147: e16-e24, 2021 03.
Article in English | MEDLINE | ID: mdl-33189916

ABSTRACT

OBJECTIVE: Traumatic brain injury (TBI) is a health problem worldwide, and therapeutic strategies to enhance brain tissue repair to lessen neurologic sequels are imperative. We aimed to analyze the impact of the inflammatory process in TBI through CXCR4 and CXCR7 chemokine receptors and their ligands' CXCL11 and CXCL12 expression profile in search for potential new druggable targets. METHODS: Twelve pericontusional tissues from severe TBI patients submitted to surgical treatment, and 20 control brain tissues from normal autopsy were analyzed for expression profile by real-time quantitative-polymerase chain reaction. CXCR7 and CXCR4 protein expressions were analyzed by immunohistochemistry. The findings were correlated with the clinical evolution. RESULTS: Increased gene expression of both receptors and their ligands was observed in TBI compared with controls, presenting high sensitivity and specificity to differentiate TBI from normal control (area under the curve ranging from 0.85 to 0.98, P < 0.001). In particular, CXCR7 expression highly correlated with CXCR4 and both ligands' expressions in TBI. Higher immunoreactions for CXCR7 and CXCR4 were identified in neurons and endothelial cells of TBI samples compared with controls. The patients presenting upregulated chemokine expression levels showed a trend toward favorable clinical evolution at up to 6 months of follow-up. CONCLUSIONS: The neuroprotective trend of CXCR4, CXCR7, CXCL11, and CXCL12 in TBI observed in this initial analysis warrants further studies with more patients, analyzing the involved signaling pathways for the development of new therapeutic strategies for TBI.


Subject(s)
Brain Contusion/genetics , Chemokine CXCL11/genetics , Chemokine CXCL12/genetics , Receptors, CXCR4/genetics , Receptors, CXCR/genetics , Adult , Aged , Brain Contusion/metabolism , Brain Injuries, Traumatic/genetics , Brain Injuries, Traumatic/metabolism , Case-Control Studies , Chemokine CXCL11/metabolism , Chemokine CXCL12/metabolism , Female , Gene Expression , Humans , Immunohistochemistry , Male , Middle Aged , RNA, Messenger/metabolism , Real-Time Polymerase Chain Reaction , Receptors, CXCR/metabolism , Receptors, CXCR4/metabolism , Young Adult
7.
Cancer Cell ; 35(3): 504-518.e7, 2019 03 18.
Article in English | MEDLINE | ID: mdl-30827889

ABSTRACT

Ionizing radiation (IR) and chemotherapy are standard-of-care treatments for glioblastoma (GBM) patients and both result in DNA damage, however, the clinical efficacy is limited due to therapeutic resistance. We identified a mechanism of such resistance mediated by phosphorylation of PTEN on tyrosine 240 (pY240-PTEN) by FGFR2. pY240-PTEN is rapidly elevated and bound to chromatin through interaction with Ki-67 in response to IR treatment and facilitates the recruitment of RAD51 to promote DNA repair. Blocking Y240 phosphorylation confers radiation sensitivity to tumors and extends survival in GBM preclinical models. Y240F-Pten knockin mice showed radiation sensitivity. These results suggest that FGFR-mediated pY240-PTEN is a key mechanism of radiation resistance and is an actionable target for improving radiotherapy efficacy.


Subject(s)
Brain Neoplasms/therapy , Cell Nucleus/metabolism , Glioma/therapy , PTEN Phosphohydrolase/metabolism , Pyrimidines/administration & dosage , Radiation Tolerance/drug effects , Receptor, Fibroblast Growth Factor, Type 2/metabolism , Animals , Brain Neoplasms/metabolism , DNA Repair/drug effects , Female , Glioma/metabolism , Humans , Male , Mice , Phosphorylation/drug effects , Pyrimidines/pharmacology , Rad51 Recombinase/metabolism , Tyrosine/metabolism , Xenograft Model Antitumor Assays
8.
World Neurosurg ; 122: e1536-e1541, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30471445

ABSTRACT

OBJECTIVE: To review the published data to create a more comprehensive natural history of multiple meningiomas (MM). METHODS: A review of MM published until now was carried out through a Medline search up to August 2018. The use of the "multiple meningiomas" keyword returned 278 articles, and the characteristics analyzed in our present cohort were searched on those publications. Articles without detailed description of clinical findings, neuroimaging confirmation of tumor multiplicity, follow-up at least of 5 years, and clear description of clinical findings were excluded. We added series to this review. RESULTS: 293 patients with MM were analyzed: 220 women and 73 men, with a total of 932 tumors (3.1 tumors per patient). The majority of tumors were located in the convexity (653% to 74.5%). The total number of tumors treated was 429 (43.9%): 338 (78.8%) by surgical resection and 91 (21.2%) by radiotherapy. Histopathologic description was available in 303 of 429 cases, being grade I in 272 (90.3%) cases, with a predominance of the meningothelial subtype (30.7%). Tumor recurrence was described in 32 (8.07%) among 397 and only 10 deaths (3.4%) of 281 reported cases, where this characteristic was evaluated. CONCLUSIONS: World Health Organization grade I predominance was observed among multiple meningiomas in similarity to single meningiomas. Only a fraction of MM patients (43.89%) needed treatment. A benign tumor behavior was corroborated by the observed low frequency of recurrence and mortality.


Subject(s)
Meningeal Neoplasms , Meningioma , Neoplasms, Multiple Primary , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Humans , Male , Meningeal Neoplasms/epidemiology , Meningeal Neoplasms/pathology , Meningeal Neoplasms/surgery , Meningioma/epidemiology , Meningioma/pathology , Meningioma/surgery , Middle Aged , Neoplasm Grading , Neoplasm Recurrence, Local , Neoplasms, Multiple Primary/epidemiology , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/surgery
9.
PLoS One ; 10(8): e0135831, 2015.
Article in English | MEDLINE | ID: mdl-26313749

ABSTRACT

Gene set analysis aims to identify predefined sets of functionally related genes that are differentially expressed between two conditions. Although gene set analysis has been very successful, by incorporating biological knowledge about the gene sets and enhancing statistical power over gene-by-gene analyses, it does not take into account the correlation (association) structure among the genes. In this work, we present CoGA (Co-expression Graph Analyzer), an R package for the identification of groups of differentially associated genes between two phenotypes. The analysis is based on concepts of Information Theory applied to the spectral distributions of the gene co-expression graphs, such as the spectral entropy to measure the randomness of a graph structure and the Jensen-Shannon divergence to discriminate classes of graphs. The package also includes common measures to compare gene co-expression networks in terms of their structural properties, such as centrality, degree distribution, shortest path length, and clustering coefficient. Besides the structural analyses, CoGA also includes graphical interfaces for visual inspection of the networks, ranking of genes according to their "importance" in the network, and the standard differential expression analysis. We show by both simulation experiments and analyses of real data that the statistical tests performed by CoGA indeed control the rate of false positives and is able to identify differentially co-expressed genes that other methods failed.


Subject(s)
Algorithms , Brain Neoplasms/genetics , Computational Biology/methods , Computer Graphics , Gene Expression Profiling , Gene Regulatory Networks , Oligonucleotide Array Sequence Analysis/methods , Biomarkers, Tumor/genetics , Gene Expression Regulation , Humans , Models, Biological
10.
Pathol Oncol Res ; 21(2): 229-40, 2015 Apr.
Article in English | MEDLINE | ID: mdl-24970694

ABSTRACT

The CXCR7, a new receptor for CXCL12 with higher affinity than CXCR4 has raised key issues on glioma cell migration. The aim of this study is to investigate the CXCR7 mRNA expression in diffuse astrocytomas tissues and to evaluate its interactions with CXCR4 and HIF1α expression and IDH1 mutation. CXCR7, CXCR4 and HIF1α mRNA expression were evaluated in 129 frozen samples of astrocytomas. IDH1 mutation status was analyzed with gene expressions, matched with clinicopathological parameters and overall survival time. Protein expression was analyzed by immunohistochemistry in different grades of astrocytoma and in glioma cell line (U87MG) by confocal microscopy. There was significant difference in the expression levels of the genes studied between astrocytomas and non-neoplasic (NN) controls (p < 0.001). AGII showed no significant correlation between CXCR7/HIF1α (p = 0.548); there was significant correlation between CXCR7/CXCR4 (p = 0.042) and CXCR7/IDH1 (p = 0.008). GBM showed significant correlations between CXCR7/CXCR4 (p = 0.002), CXCR7/IDH1 (p < 0.001) and CXCR7/HIF1α (p = 0.008). HIF1α overexpression was associated with higher expressions of CXCR7 (p = 0.01) and CXCR4 (p < 0.0001), while IDH1 mutation was associated with lower CXCR7 (p = 0.009) and CXCR4 (p = 0.0005) mRNA expressions. Protein expression increased with malignancy and in U87MG cell line was mainly localized in the cellular membrane. CXCR7 was overexpressed in astrocytoma and correlates with CXCR4 and IDH1 in AGII and CXCR4, IDH1 and HIF1α in GBM. Overexpression HIF1α was related with higher expressions of CXCR7 and CXCR4, otherwise IDH1 mutation related with lower expression of both genes. No association between CXCR7 and CXCR4 expression and survival data was related.


Subject(s)
Astrocytoma/metabolism , Brain Neoplasms/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Isocitrate Dehydrogenase/genetics , Mutation/genetics , Receptors, CXCR4/metabolism , Receptors, CXCR/metabolism , Astrocytoma/genetics , Astrocytoma/pathology , Brain Neoplasms/genetics , Brain Neoplasms/pathology , Carcinogenesis , Gene Expression Regulation, Neoplastic , Glioblastoma/genetics , Glioblastoma/metabolism , Glioblastoma/pathology , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Immunohistochemistry , Isocitrate Dehydrogenase/metabolism , Kaplan-Meier Estimate , Neoplasm Grading , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, CXCR/genetics , Receptors, CXCR4/genetics , Up-Regulation
11.
Oncotarget ; 3(7): 709-22, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22869205

ABSTRACT

Mutations in the critical chromatin modifier ATRX and mutations in CIC and FUBP1, which are potent regulators of cell growth, have been discovered in specific subtypes of gliomas, the most common type of primary malignant brain tumors. However, the frequency of these mutations in many subtypes of gliomas, and their association with clinical features of the patients, is poorly understood. Here we analyzed these loci in 363 brain tumors. ATRX is frequently mutated in grade II-III astrocytomas (71%), oligoastrocytomas (68%), and secondary glioblastomas (57%), and ATRX mutations are associated with IDH1 mutations and with an alternative lengthening of telomeres phenotype. CIC and FUBP1 mutations occurred frequently in oligodendrogliomas (46% and 24%, respectively) but rarely in astrocytomas or oligoastrocytomas ( more than 10%). This analysis allowed us to define two highly recurrent genetic signatures in gliomas: IDH1/ATRX (I-A) and IDH1/CIC/FUBP1 (I-CF). Patients with I-CF gliomas had a significantly longer median overall survival (96 months) than patients with I-A gliomas (51 months) and patients with gliomas that did not harbor either signature (13 months). The genetic signatures distinguished clinically distinct groups of oligoastrocytoma patients, which usually present a diagnostic challenge, and were associated with differences in clinical outcome even among individual tumor types. In addition to providing new clues about the genetic alterations underlying gliomas, the results have immediate clinical implications, providing a tripartite genetic signature that can serve as a useful adjunct to conventional glioma classification that may aid in prognosis, treatment selection, and therapeutic trial design.


Subject(s)
Brain Neoplasms/classification , DNA Helicases/genetics , DNA-Binding Proteins/genetics , Glioma/classification , Isocitrate Dehydrogenase/genetics , Mutation , Nuclear Proteins/genetics , Repressor Proteins/genetics , Adult , Brain Neoplasms/genetics , Brain Neoplasms/pathology , Female , Gene Silencing , Glioma/genetics , Glioma/pathology , Humans , Immunohistochemistry , Male , Neoplasm Grading , Prognosis , RNA-Binding Proteins , Telomere/genetics , X-linked Nuclear Protein
12.
Rev. cuba. estomatol ; 48(4): 410-415, oct.-dic. 2011.
Article in Spanish | LILACS, CUMED | ID: lil-615141

ABSTRACT

La distrofia muscular de Steinert tipo 1 afecta frecuentemente a los músculos de la masticación y puede causar debilidad muscular y alteraciones bucofaciales. Esta enfermedad se caracteriza por presentar el fenómeno de anticipación, en el cual la descendencia de una persona afectada desarrolla la enfermedad de manera más precoz. El objetivo de este trabajo fue reportar 2 casos de una madre y su hija con diagnóstico de distrofia muscular de Steinert. Se realizó un análisis de las características clínicas bucales y los efectos del fenómeno de anticipación de esta enfermedad mediante el examen odontológico, la medición de la fuerza masticatoria y la resonancia magnética nuclear de la articulación temporomandibular. La expresión clínica de la enfermedad fue más precoz en la hija que en la madre, lo que se relacionó con un mayor número de estructuras dentarias perdidas y de cambios degenerativos en la articulación temporomandibular, asociados a una menor fuerza masticatoria(AU)


ABSTRACT The Steinert's muscular dystrophy type 1 involves frequently the masticatory muscle causing muscular weakness and orofacial alterations; this entity is characterized by to present the anticipatory phenomenon where la offspring of a involved person develops the disease in an early way. The aim of present paper is to report 2 cases in mother and daughter diagnosed with the DM1 and to analyze the oral clinical features and the effects of anticipatory phenomenon of disease by stomatologic examination, measurement of masticatory strength and magnetic nuclear resonance of temporomandibular joint. The clinical expression of this disease was earlier in the daughter than in the mother, which was related to a greater number of lost teeth and of degenerative changes en la TMJ associated with a lesser masticatory strength(AU)


Subject(s)
Humans , Female , Adult , Middle Aged , Temporomandibular Joint/diagnostic imaging , Bite Force , Myotonic Dystrophy/diagnosis
13.
Am J Trop Med Hyg ; 83(2): 271-3, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20682866

ABSTRACT

Severe rhabdomyolysis (creatine phosphokinase = 29,400 U/L) developed in a 16-year-old boy from Manaus, Brazil, after he started treatment with chloroquine for infection with Plasmodium vivax. Treatment led to myoglobinuria and acute renal failure. After hemodialysis, the patient improved and a muscle biopsy specimen showed no myophosphorylase or deaminase deficiency. This case of rhabdomyolysis associated with P. vivax infection showed no comorbidities. The pathogenesis is still unclear. Although rhabdomyolysis is generally reported as a complication of Plasmodium falciparum malaria, leading to metabolic and renal complications,1 it has been reported in a patient with P. vivax infection with myoadenylate deaminase deficiency.2 We report a case in a patient without typical muscle enzyme deficiencies in which severe rhabdomyolysis developed while the patients was being treated with chloroquine for a confirmed P. vivax infection.


Subject(s)
Malaria, Vivax/complications , Plasmodium vivax , Rhabdomyolysis/parasitology , Adolescent , Animals , Brazil , Humans , Malaria, Vivax/drug therapy , Male , Rhabdomyolysis/complications
14.
Biochim Biophys Acta ; 1769(7-8): 437-42, 2007.
Article in English | MEDLINE | ID: mdl-17588684

ABSTRACT

Comparative analysis of cancer stem cells with their neoplastic and non-neoplastic counterparts should help better understand the underlying molecular events leading to transformation and tumor dissemination. Here, we report a molecular signature comprised by genes with exclusive aberrant expression in CD133(+) cells, a reported subpopulation of tumorigenic stem-like cells, isolated from human glioblastomas. Microarrays covering 55,000 transcripts were used to compare gene expression profiles in purified subpopulations of CD133(+) and CD133(-) GBM cells. Sixteen genes, many of which not previously associated with astrocytomas, were found aberrantly expressed in CD133(+) cells, but not in CD133(-), when compared with corresponding non-neoplastic controls. Up-regulation of two of such genes, E2F2 and HOXC9, was detected in a set of 54 astrocytomas of different grades and significantly associated with malignancy. Due to their distinctive expression in CD133(+) cells, the use of E2F2 and HOXC9 as therapeutic targets for tumor eradication is suggested.


Subject(s)
Astrocytes/pathology , Astrocytoma/metabolism , Cell Transformation, Neoplastic/pathology , E2F2 Transcription Factor/biosynthesis , Homeodomain Proteins/biosynthesis , Gene Expression Profiling , Humans , Tumor Cells, Cultured , Up-Regulation
15.
Cancer Lett ; 224(2): 321-7, 2005 Jun 28.
Article in English | MEDLINE | ID: mdl-15914282

ABSTRACT

Alteration in TP53 is the most common genetic event reported for many tumors, including astrocytomas. The majority of studies, on analyzing TP53 mutations, have not included all splice junctions. Consequently, splice site mutations are thought to be relatively infrequent. TP53 were examined for mutations by polymerase chain reaction, single strand conformation polymorphism and direct sequencing in cases of diffuse astrocytomas. We found TP53 mutations in 17.8% (8 out of 45) of the tumors tested: 3 splicing, 3 missense and 2 silent mutations. We have shown that splice site mutations of TP53 are more frequent than previously reported. These findings emphasize the importance of thorough screening of TP53 mutations in gliomas.


Subject(s)
Astrocytoma/genetics , Brain Neoplasms/genetics , Genes, p53 , RNA Splice Sites , DNA Mutational Analysis , Humans , Mutation, Missense , Polymerase Chain Reaction
16.
Epilepsy Behav ; 4(2): 133-41, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12697137

ABSTRACT

We investigated a series of patients with epileptic psychosis in Brazil and compared our findings with those of other authors. We evaluated 38 outpatients with epileptic psychosis with a semistructured clinical interview, Annett inventory for hand dominance, international classifications for seizures and syndromes, and DSM-IV for psychosis diagnoses. We studied course and outcome for epilepsy and psychosis. Gender distribution was approximately even. Epilepsy and psychiatric disorders among relatives and early CNS insults in personal histories were frequent findings. Mean age of epilepsy onset was 9.3 years. Epilepsy started before psychosis in all cases, and evolved to clinical refractoriness. There was a predominance of temporal lobe epilepsy. Mean age of psychosis onset was 27.4 years, after a mean duration of epilepsy of 18.1 years, with predominance of schizophrenic presentations with interictal onset, frequent psychiatric admissions, suicide attempts, and postpsychosis functional decline. Tumors or lesions of an embryologic nature were uncommon, but mesial temporal sclerosis was frequent.


Subject(s)
Epilepsy/epidemiology , Psychotic Disorders/epidemiology , Adult , Aged , Brazil/epidemiology , Comorbidity , Diagnostic and Statistical Manual of Mental Disorders , Employment/statistics & numerical data , Epilepsy/diagnosis , Female , Health Status , Humans , Male , Middle Aged , Prevalence , Psychotic Disorders/diagnosis , Psychotic Disorders/genetics , Severity of Illness Index , Time Factors
17.
Arq. neuropsiquiatr ; 58(4): 1002-8, Dec. 2000.
Article in English | LILACS | ID: lil-273838

ABSTRACT

This is a retrospective study of 21 surgically treated patients with temporal lobe tumors and epilepsy. Evaluation included clinical data, EEG findings, structural scans, pathological diagnosis and post-surgical follow-up. There were 9 cases of ganglioglioma, 5 pilocytic astrocytoma, 3 ganglioneuroma, 2 dysembryoplastic neuroepithelial tumor, 1 pleomorphic xantoastrocytoma, and 1 meningioangiomatosis. Mean follow-up time was 22 months and outcome was evaluated according to Engel's classification; 76.2 percent were classified in class I and 23.8 percent in II and III. All patients classes II and III had been submitted to mesial and neocortical resections. There were no differences related to clinical characteristics, pathological diagnosis or duration of follow-up in patients seizure-free or not. All patients had abnormal MRI and ten of these had normal CT; the MRI characteristics were compared to pathological diagnosis and specific histological characteristics of the tumors were not discernible by MRI. We concluded that MRI was essential for the diagnosis and precise location of TL tumors. Ganglioglioma was the most frequent tumor and lesionectomy associated to mesial resection doesn't guarantee a better prognosis


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Brain Neoplasms/surgery , Epilepsy, Temporal Lobe/surgery , Temporal Lobe/surgery , Brain Neoplasms/complications , Brain Neoplasms/diagnosis , Epilepsy, Temporal Lobe/diagnosis , Epilepsy, Temporal Lobe/etiology , Follow-Up Studies , Magnetic Resonance Imaging , Neoplasm Staging , Prognosis , Retrospective Studies , Tomography, X-Ray Computed , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...